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Abstract
AIM: To identify molecular biologic differences between 
two gastric adenocarcinoma subgroups presenting dif-
ferent prognoses through the analysis of microRNA and 
protein expression.
METHODS: Array technologies were used to generate 
1146 microRNAs and 124 proteins expression profiles 
of samples from 60 patients with gastric cancer. For the 
integrative analysis, we used established mRNA expres-
sion data published in our previous study. Whole mRNA 
expression levels were acquired from microarray data 
for 60 identical gastric cancer patients. Two gastric 
adenocarcinoma subgroups with distinct mRNA expres-
sion profiles presented distinctly different prognoses. 
MicroRNA and protein expression patterns were com-
pared between gastric cancer tissue and normal gastric 
tissue and between two different prognostic groups. 
Aberrantly expressed microRNA, associated mRNA, and 
protein in patients with poor-prognosis gastric cancer 
were validated by quantitative reverse transcription 
polymerase chain reaction and immunochemistry in in-
dependent patients.
RESULTS: We obtained the expression data of 1146 
microRNAs and 124 cancer-related proteins. Four mi-
croRNAs were aberrantly expressed in the two prog-
nostic groups and in cancer vs  non-cancer tissues (P  
< 0.05). In the poor-prognosis group, miR-196b, miR-
135b, and miR-93 were up-regulated and miR-29c* 
was down-regulated. miR-196b expression positively 
correlated with Homeobox A10 (HOXA10) expression (r  
= 0.726, P  < 0.001), which was significantly increased 
in poor-prognosis patients (P  < 0.001). Comparing 
gastric cancer with non-cancer tissues, 46/124 proteins 
showed differential expression (P  < 0.05); COX2 (P  < 
0.001) and cyclin B1 (P  = 0.017) were clearly over-
expressed in the poor-prognosis group.
CONCLUSION: Co-activation of miR-196b and HOXA10 
characterized a poor-prognosis subgroup of patients 
with gastric cancer. Elucidation of the biologic function 
of miR-196b and HOXA10 is warranted.
© 2013 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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and progenitor cells. Its over-expression is associated with 
cancer development and poor prognosis in patients with 
acute myeloid leukemia and solid cancers[21-23]. HOXA10 
is a neighboring gene of  miR-196b but these genes have 
no known function in gastric cancer pathogenesis.
In this study, we generated microRNA and protein 
expression profiles using samples from 60 patients with 
gastric cancer to identify molecular biologic differences 
between previously identified good- and poor-prognosis 
patient subgroups. 
MATERIALS AND METHODS
Patients and samples
Tumor specimens and clinical data were obtained from 
patients with primary gastric adenocarcinoma who un-
derwent curative gastrectomy as the primary treatment 
between 1999 and 2007 at Severance Hospital and Gang-
nam Severance Hospital, Yonsei University College of  
Medicine, Seoul, South Korea. Three independent patient 
cohorts were used for each experiment: Group 1 (frozen 
tissue samples from 60 patients, each of  whom provided 
a cancer sample and 8 of  whom provided a non-cancer 
sample) for microRNA, and protein microarray analysis 
(Table 1); Group 2 (12 paired cancer and non-cancer fro-
zen tissue samples from 12 patients) for validation tests 
using quantitative reverse transcription polymerase chain 
reaction (qRT-PCR); and Group 3 (paraffin-embedded 
samples from 368 patients with gastric cancer) for tissue 
microarray immunohistochemistry (IHC). Frozen tissue 
samples were examined by pathologists at the time of  
collection and were stored below -80 ℃ at a tissue bank 
until the analysis. Samples were collected after obtaining 
written informed consent from the patients. The study 
was approved by the institutional review board of  Yonsei 
University Health System.
MicroRNA microarray
Total RNA was extracted from fresh frozen tissues using 
a mirVanaTM miRNA isolation kit (Ambion, Austin, TX, 
United States). Microarray experiments were performed 
according to the manufacturer’s protocols (Illumina mi-
croRNA Expression Profiling Assay; Illumina, San Diego, 
CA, United States). The panel contained 1146 miRNA 
assays described in the Sanger Institute miRBase Release 
12.0 (from miR-1 to miR-1827)[24]; 200 ng RNA was used 
for labeling and hybridization. Chips were scanned with 
an Illumina BeadArray Reader (Illumina, San Diego, CA, 
United States) and intensity values were analyzed using 
BeadStudio version 3.1.3. A cut-off  detection P value of  
0.01 was used to determine whether a microRNA probe 
was significantly detected. Microarray data were normal-
ized using the quantile normalization method. MicroR-
NA microarray data is available in the National Center 
for Biotechnology Information (NCBI) Gene Expression 
Omnibus (GEO) public database (accession number 
GSE26595).
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Core tip: Using an integrative analysis of the tumor 
transcriptome and protein expression profiles obtained 
by microarray techniques, we have elucidated the 
molecular biologic characteristics of a poor prognosis 
gastric cancer subgroup. Overexpression of miR196b 
and Homeobox A10 are implicated in gastric cancer, 
particularly in tumors with poor prognosis features. We 
anticipate this integrative approach will contribute to 
the characterization of cancer heterogeneity and the 
development of personalized therapy through the iden-
tification of cancer targets.
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INTRODUCTION
Gastric cancer is the second leading cause of  cancer-
related deaths worldwide[1]. Surgery is the only curative 
treatment strategy and conventional chemotherapy has 
shown limited efficacy for the treatment of  patients with 
advanced disease. Understanding the molecular mecha-
nisms governing carcinogenesis, progression, and prog-
nosis in gastric cancer is a prerequisite for the construc-
tion of  a convincing management strategy. It is widely 
acknowledged that there are favorable and poor-progno-
sis subtypes of  cancer, although the treatment strategy is 
generally determined by clinical and histopathologic stage 
rather than disease type. Patients with gastric cancer are 
also clinically heterogeneous, which suggests an underly-
ing molecular diversity[2,3]. Molecular subtypes of  gastric 
cancer have been suggested through analysis of  gene or 
protein expression profiles and oncogenic signaling path-
ways[4-9]. In a previous study, we identified distinct gastric 
cancer subclasses by analyzing gene expression profiles 
and we described two gastric cancer subtypes that were 
strongly associated with prognosis[10]. 
MicroRNAs play a role in the pathogenesis of  various 
human cancers[11]. Some microRNAs function as onco-
genes and others as tumor suppressors, although their 
mechanisms remain to be elucidated[12,13]. The relation-
ship between microRNA expression profile and gastric 
cancer prognosis has been actively explored[14,15], as has 
the pathogenesis of  gastric cancer[16,17]. Overexpression 
of  miR-196b has been linked to leukemia and several 
solid cancers including gastric cancer and may represent a 
useful gastric cancer marker[18,19]. A role for miR-196b as 
an oncogene or tumor suppressor has not yet been con-
firmed[20], nor has its role in gastric carcinogenesis and 
progression.
Homeobox A10 (HOXA10) is transcription factor 
involved in the proliferation of  hematopoietic stem cells 
Protein expression assay
Reverse-phase protein array (RPPA) was performed ac-
cording to the manufacturer’s protocol and the data were 
analyzed as previously described[25]. Frozen tissues were 
lysed in RPPA lysis buffer and complete protease inhibi-
tor cocktail (Roche Diagnostics, Mannheim, Germany). 
Protein-containing samples were diluted to a uniform 
protein concentration and transferred into 384-well 
plates. The lysate was printed onto nitrocellulose-coated 
glass slides and probed using 124 antibodies. Signal in-
tensity was measured by scanning the slides: slides were 
scanned, analyzed, and quantified using the customized 
Microvigene software (VigeneTech, Inc., Carlisle, MA, 
United States) to measure spot intensity.
Analysis of microarray data
The microarray expression level was transformed into 
a log 2 base before further analysis. Cluster analysis was 
performed after median centering using the Cluster 3.0 
program and visualized in Treeview (Eisen Lab. CA, 
United States). BRB-ArrayTools (version 3.6; Biometrics 
Research Branch, National Cancer Institute, MD, United 
States) were used for microarray data analysis[26]. The pre-
viously generated gene expression data from the poor-
prognosis group[10] were obtained from the NCBI GEO 
public database (accession number GSE13861). 
Quantitative RT-PCR and analysis
Quantitative RT-PCR was carried out according to the 
manufacturer’s protocols (miRURY LNA microRNA 
PCR System, Exiqon, Vedbaek, Denmark) and was per-
formed in duplicate. The RT reactions were incubated 
for 30 min at 50 ℃ followed by heat inactivation at 85 ℃ 
for 5-10 min. cDNA templates were diluted and added 
to the PCR master mix. Cycling conditions were as fol-
lows: 37 ℃ for 10 min, 95 ℃ for 10 min, followed by 40 
cycles of  95 ℃ for 20 s and 60 ℃ for 60 s. RT-PCR was 
performed on a 7900HT Fast Real-Time PCR System 
(Applied Biosystems, Foster City, CA, United States) with 
a 96-well block module. Relative amounts of  microRNA 
were calculated from the threshold cycle (CT) number us-
ing the expression of  U6 snRNA for normalization.
Tissue microarray construction and IHC staining
Paraffin-embedded tissue microarray blocks were created 
using gastric cancer tissue specimens obtained from 368 
patients. A tissue microarray set contained 14 slides with 
30 tissue cores per slide. Sections 4 μm thick were depa-
raffinized and treated to block endogenous peroxidase 
activity. After antigen retrieval, the primary antibody - 
anti-HOXA10 antibody (polyclonal, dilution 1:75; Santa 
Cruz Biotechnology, Santa Cruz, CA, United States) - 
was applied to the sections. The sections were incubated 
with a secondary antibody (horse radish peroxidase-
rabbit/mouse), developed using a NovaRED substrate 
kit (VECTOR Laboratory, Burlingame, CA, United 
States) and counterstained with Harris hematoxylin. 
Stained slides were examined with a Zeiss Axio Imager 
M2 microscope with an AxioCam HRc camera and pho-
tographed using AxioVision 4.8.2 software (Zeiss, Jena, 
Germany). Strong cytoplasmic staining was considered 
as positive expression. Positive expression was defined as 
staining stronger compared to smooth muscle. Negative 
expression was defined as staining positivity lower than 
or similar to smooth muscle.
Statistical analysis
Statistical analysis was performed with PASW Statistics 
18 (SPSS Inc., San Diego, United States) and graphical 
interpretations were generated with GraphPad Prism 
5 (GraphPad Software, San Diego, CA, United States). 
The Kaplan-Meier method was used to estimate patient 
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Table 1  Clinicopathologic factors of patients with gastric cancer participating in the microarray analysis  n  (%)
Characteristic Group 1 
(n  = 60)
miR-196b high 
(n  = 28)
miR-196b low 
(n  = 29)
P  value HOXA10 high 
(n  = 29)
HOXA10 low 
(n  = 28)
P  value
Age, yr
   Median (range)      63 (32-83)      66 (34-78)      58 (32-83) 0.134      64 (34-83)      60 (32-78) 0.134
   > 65 15 (52)   9 (32) 15 (52)   9 (32)
Sex
   Male 41 (68) 19 (68) 20 (69) 0.928 18 (62) 21 (75) 0.294
Histologic type
   Diffuse 27 (45)   9 17 0.066   8 18 0.007
   Intestinal 23 (38) 14   9 16   7
   Mixed 10 (17)   5   3   5   3
T stage
   T1/T2 26 (43) 10 (36) 14 (48) 0.337 11 (38) 13 (46) 0.516
   T3/T4 34 (57) 18 (64) 15 (52) 18 (62) 15 (54)
N stage
   N0/N1 36 (60) 15 (54) 19 (66) 0.358 16 (55) 18 (64) 0.483
   N2/N3 24 (40) 13 (46) 10 (34) 13 (45) 10 (36)
AJCC stage1
   Ⅰ/Ⅱ 23 (38) 11 (39) 12 (41) 0.872 11 (38) 12 (43) 0.705
   Ⅲ/Ⅳ 37 (62) 17 (61) 17 (59) 18 (62) 16 (57)
1Based on the American Joint Committee on Cancer staging manual 6th edition. HOXA10: Homeobox A10; AJCC: American Joint Committee on Cancer.
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els are shown in Figure 3A. miR-196b showed the most 
significantly different expression patterns between cancer 
and non-cancer samples (P < 0.001), and between the C1 
and C2 groups (P < 0.001).
Validation of microRNA expression by quantitative 
RT-PCR
To validate the microRNA expression microarray data, 
qRT-PCR was performed using RNA from the 12 pa-
tients in Group 2. Using CT numbers, miR-196b was 
determined to be up-regulated in gastric cancer tissue 
compared with non-cancer tissue (P = 0.007; two-sample 
paired t test; Figure 3B). The up-regulation of  miR-135b 
in gastric cancer samples was not statistically significant (P 
= 0.118).
Correlation between HOXA10 and miR-196b expression
HOXA9 and HOXA10 are neighboring genes to miR-
196b (Figure 4A) and are regarded as miR-196b-
associated genes. Therefore, the expression level of  
HOXA9 and HOXA10 and their correlation with miR-
196b expression were evaluated. Analysis of  microRNA 
and mRNA expression data from gastric cancer tissue 
samples obtained from patients in Group 1 showed that 
HOXA10 mRNA expression was positively correlated 
with miR-196b expression (Figure 4B; r = 0.726, P < 
0.001). HOXA10 expression was up-regulated in gastric 
cancer compared with non-cancer tissue and was higher 
in C1 compared with C2 patients (Figure 4C). Overex-
pression of  miR-196b was significantly associated with 
shorter overall survival (OS; P = 0.022; Figure 4D). Over-
expression of  HOXA10 exhibited a tendency to poor 
OS (P = 0.202; Figure 4D) but HOXA9 did not exhibit 
any significant association with miR-196b or prognosis 
(Figure 4B and D). HOXA10 protein-positive expression 
was identified in 56 of  368 gastric cancer tissue samples 
(15.2%) from patients in Group 3 (Figure 5A and B). In 
non-cancer gastric tissue, body glands were stained vari-
ably. In contrast to well and moderately differentiated ad-
enocarcinoma, poorly differentiated adenocarcinoma and 
signet ring cell carcinomashowed less positive staining for 
HOXA10 (29.4% vs 8.4%, P < 0.001).
Protein expression profile of gastric cancer
The unsupervised clustering analysis revealed that protein 
expression was highly variable compared with mRNA 
and microRNA expression in non-cancer and cancer tis-
sues. Two-group two-sample t tests comparisons were 
performed using cancer and non-cancer samples to iden-
tify gastric cancer-specific proteins. Univariate analyses 
revealed 48 out of  124 proteins with significantly dif-
ferent levels (P < 0.05) between cancer and non-cancer 
tissues (Figure 5B). Among these 48 proteins, the expres-
sion of  COX2 and cyclin B1 was significantly increased 
in gastric cancer vs non-cancer tissue (both P < 0.001), 
and up-regulated in the C1 compared with C2 groups (P 
< 0.001 for COX2 and P = 0.016 for cyclin B1).
prognosis; differences between genotypes were compared 
using the log-rank test. Differences between groups were 
analyzed using the two-tailed Student’s t test and the χ 2 
test. Associations between the expression levels of  the 
two targets were analyzed using the Pearson correlation 
coefficient. Generally, differences were considered statis-
tically significant at P < 0.05. 
RESULTS
Gene expression microarray-established gastric cancer 
subgroups C1 and C2
In our previous study[10], two gastric cancer subgroups [a 
poor-prognosis group C1 (n = 32) and a good-prognosis 
group C2 (n = 28)] were established through unsuper-
vised hierarchical clustering of  gene expression data from 
the 60 patients with gastric cancer in Group 1. Genes 
with expression levels that were at least 2-fold different 
in at least 15 tissues, relative to the median value across 
tissues, were selected for hierarchical clustering analysis 
(2077 gene features) (Figure 1A). Following comparison 
of  gene expression profiles of  samples from C1, C2, 
and non-cancer patients, unique gene sets were identified 
for the C1 and C2 groups that contained 2755 and 1437 
genes, respectively (P < 0.001). C1 patients had signifi-
cantly poorer relapse-free survival than C2 patients (P = 
0.0019; log-rank test). This was independent of  disease 
stage, indicating that the molecular features reflected in 
gene expression patterns might be strong independent 
predictors of  clinical outcome (Figure 1B). Gene expres-
sion data for 5922 transcription factor (TF) genes were 
selected and C1-specific TF genes were extracted (Figure 
1C). A total of  413 up-regulated and 326 down-regulated 
TF genes are shown in Figure 1D; the top 20 up- and 
down-regulated TF genes are listed in Figure 1E.
microRNA expression profile of gastric cancer
A total of  410 out of  1146 probes in the microRNA 
expression assay were significantly detected (P < 0.01) 
and further processed (Figure 2A). Though unsupervised 
clustering analysis revealed two major subtypes, these did 
not appear to have any prognostic or clinico-pathologic 
value. Subsequently, 164 microRNAs significantly (P < 
0.05 in the t test) aberrantly expressed in gastric cancer 
tissue were identified (Figure 2A). Non-cancer tissue 
showed relatively homogenous microRNA expression 
patterns, in contrast to the highly heterogeneous expres-
sion patterns observed in cancer tissues.
Aberrant microRNA expression in C1 and C2 patients
MicroRNA expression data were compared between 
non-cancer and cancer tissues and between C1 and C2 
samples. Four microRNAs were uniquely dysregulated (P 
< 0.05) among non-cancer, C1, and C2 samples (Figure 
2A). miR-196b, miR-135b, and miR-93 were up-regulated 
and miR-29c* was down-regulated in the C1, poor-prog-
nosis group (Figure 2B). Log-transformed expression lev-
Lim JY et al . miR-196b and HOXA10 in gastric cancer
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DISCUSSION
We previously identified two prognostic subgroups of  
patients with gastric cancer through gene expression mi-
croarray technology[10]. Our findings suggested that their 
gene expression signatures reflected clinical differences 
between good- and poor-prognosis patients independent 
of  tumor-node-metastasis stage and histology. The mo-
lecular biologic mechanisms responsible for these clinical 
differences were unknown. In an effort to understand 
these molecular mechanisms, we obtained microRNA 
and protein expression data from tumor tissue samples 
using high-throughput microarray techniques.
First, two-group comparison analysis revealed 164 mi-
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Figure 1  Two prognostic groups of patients with gastric cancer, C1 and C2, have distinct mRNA expression patterns. A: mRNA expression patterns of gastric 
cancer and non-cancer gastric tissue are depicted in a heat map. Hierarchical clustering revealed two subtypes of gastric cancer, C1 and C2. The data are presented 
as a matrix in which rows represent individual mRNAs and columns represent each tissue. The color red represents relatively high expression levels and green re-
flects lower expression levels; B: Kaplan-Meier plot of relapse-free survival (RFS) revealed C1 and C2 represented poor- and good-prognosis gastric cancer tissues, 
respectively; C: Workflow of C1-specific 739 transcription factors (TFs) selected from a total 5,922 TFs; D: Hierarchical clustering of gene expression for 739 TF 
genes; E: List of top 20 up- and down-regulated TF genes in the C1 group. 
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1146 microRNA assays
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Figure 2  Aberrant microRNA expression in gastric cancer. A: Flowchart of the data analysis to identify poor-prognosis C1-specific microRNAs. Four microRNAs 
(miR-196b, miR-135b, miR-93, and miR-29c*) were selected; B: Expression patterns of the four microRNAs are shown in a heat map for C1, C2, and non-cancer gas-
tric tissues. The color yellow represents relatively high expression levels and blue reflects relatively low levels.
Lo
g 
tr
an
sf
or
m
ed
 e
xp
re
ss
io
n 
le
ve
l
14
12
10
8
0
Non-cancer         cancer                C2                  C1
                                   miR-196b
Lo
g 
tr
an
sf
or
m
ed
 e
xp
re
ss
io
n 
le
ve
l
14
12
10
8
0
Non-cancer         cancer                C2                  C1
                                     miR-93
P  < 0.001 P  < 0.001
P  < 0.001 P  = 0.003
14
12
10
8
0
Non-cancer         cancer                C2                  C1
                                     miR-135b
P  < 0.001 P  = 0.018
14
12
10
8
0
Non-cancer         cancer                C2                  C1
                                     miR-29c*
P  < 0.001 P  = 0.011
A
Lo
g 
tr
an
sf
or
m
ed
 e
xp
re
ss
io
n 
le
ve
l
miR-196b
P  = 0.007
Non-cancer               cancer
miR-135b
P  = 0.118
Non-cancer               cancer
B
Figure 3  The expression levels of four microRNAs. A: Four microRNAs expressed differentially in gastric tissues. Scatter plots of gene expression levels with a 
bar indicating the mean; B: The expression level of miR-196b and miR-135b were validated in a quantitative reverse transcription polymerase chain reaction study of 
12 patients samples. 
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croRNAs that showed different expression profiles in the 
cancer and non-cancer tissue samples. Supervised cluster-
ing (C1 vs C2 vs non-cancer) using these 164 microRNAs 
revealed that non-cancer tissues manifested relatively ho-
mogenous microRNA expression. A comparison of  the 
microRNA expression revealed that three microRNAs 
(miR-196b, miR-135b, and miR-93) were up-regulated in 
C1 vs C2 and in cancer vs non-cancer tissues. Conversely, 
miR-29c* was down-regulated in C1 samples. We suggest, 
therefore, that dysregulation of  those four microRNAs 
might characterize C1, our previously identified poor-
prognosis gastric cancer subgroup. The accumulated 
knowledge about microRNA-associated genes and can-
cers is summarized in Table 2.
The overexpression of  miR-196b has previously been 
linked to leukemia and several solid cancers[18,19]. The 
increased expression of  miR-196b contributes to the 
development of  leukemia and the relationship between 
differential miR-196b expression and clinical and biologic 
features has been studied in leukemia[18,39-41]. miR-196b 
expression is also increased in pancreatic ductal adenocar-
cinoma and bronchial squamous cell carcinoma, although 
its role in these cancers has not been established[27,28]. Tsai 
et al[19] reported that a lack of  promoter methylation in 
miR-196b resulted in its overexpression in gastric cancer 
cell lines and patient samples, and they proposed that 
miR-196b overexpression might provide a useful tumor 
marker. However, it has not yet been determined whether 
miR-196b functions as an oncogene or a tumor suppres-
sor[20], and its role in gastric carcinogenesis and progres-
sion has not yet been identified.
In recent in vitro study, a leukemia oncogene was found 
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Figure 4  The correlation between miR-196b and homeobox A10 expression in gastric cancer. A: miR-196b, homeobox A10 (HOXA10), and HOXA9 are neigh-
bor genes and located on chromosome 7p15.2; B: Expression of miR-196b and HOXA10 were positively correlated (r = 0.726; P < 0.001). The correlation between 
miR-196b and HOXA9 expression was less significant; C: HOXA10 and HOPXA9 expression level in gastric cancer vs non-cancer tissues and in the C1 vs the C2 
group. Results are presented as means with 95%CI; D: Kaplan–Meier plot of overall survival according to the expression level of miR-196b, HOXA10, and HOXA9. 
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to promote the expression of  miR-135b, with elevated 
miR-135b expression decreasing chemosensitivity, sug-
gesting the contribution of  miR-135b to the oncogenic 
activity of  the leukemia oncogene[29]. It has been suggest-
ed that oncogenic kinase-linked miR-135b contributes to 
tumorigenesis through modulation of  the tumor-immune 
phenotype and microenvironment[29]. Others have identi-
fied miR-135b as a novel biomarker for pancreatic ductal 
adenocarcinoma[30]. In chronically inflamed or genetic 
models of  colon cancer, miR-135b was suggested along 
with other microRNAs, to regulate signaling pathways re-
lated to mitogen-activated protein kinase, phosphoinosit-
ide 3-kinase, WNT, and transforming growth factor 
(TGF)-β, all of  which are known to be involved in cell 
transformation[31]. However, there are as of  yet no data 
relating to the pathogenesis of  gastric cancer.
miR-93 is a well-known constituent of  the miR-106b 
approximately 25 cluster, paralogs of  which have onco-
genic activity in several cancers, including gastric cancer. 
Up-regulated miR-93 in gastric cancer leads to cell cycle 
activation and impaired apoptosis[17,32]. miR-29c* is, how-
ever, poorly understood with no known target and it has 
only been shown to be an independent favorable prog-
nostic factor in malignant pleural mesothelioma[38].
Information about each of  these microRNAs pro-
vides support for the proposal that our poor-prognosis 
microRNA signature - up-regulation of  miR-196b, miR-
135b, and miR-93 and down-regulation of  miR-29c* - 
is relevant. As miR-93 has largely been investigated in 
gastric cancer and miR-29c* is poorly understood, we 
focused our attention on miR-196b and miR-135b. The 
qRT-PCR assay demonstrated that miR-196b was signifi-
cantly overexpressed in cancer vs non-cancer tissue while 
miR-135b was not (Figure 3B). Therefore, the role of  
miR-196b in gastric cancer was further investigated.
Using correlation analysis, we identified that HOXA10 
levels were also elevated in gastric cancer. The expression 
of  miR-196b appears to be most positively associated 
with HOXA10 expression. Our previous gene expression 
microarray data indicated that HOXA10 was ranked as 
the second most up-regulated TF in gastric cancer (Figure 
1E), as it was significantly elevated in gastric cancer vs 
non-cancer and in poor-prognosis C1 vs good-prognosis 
C2. Evidence is accumulating that HOXA10 is involved 
in the proliferation of  hematopoietic stem cells and 
progenitor cells, leading to cancer development through 
activating the target genes coding for TGFβ2, dual-
specificity protein phosphatase 4, and integrin-β3[21,42,43]. 
Up-regulation of  HOX genes is associated with a tu-
mor stem-like cell phenotype of  glioblastoma, and high 
HOXA10 protein expression has been associated with 
resistance to chemotherapy[44]. HOXA10 is also over-ex-
pressed in a poor-prognosis subset of  patients with acute 
myeloid leukemia and in several solid cancers[21-23]. On the 
basis of  these findings, we postulate that HOXA10 may 
induce gastric carcinogenesis and function as a marker of  
poor prognosis. Recently, it was reported that upregula-
tion of  HOXA10 was correlated with favorable progno-
sis and inversely correlated with the depth of  invasion in 
gastric cancer[45]. Different patient populations and detec-
tion methods for HOXA10 seems to be responsible for 
inconsistent results. More reliable evidences should be 
accumulated to elucidate the role of  HOXA10 in gastric 
cancer.
miR-196b is located in the HOXA cluster on chro-
mosome 9 and expression levels of  pri-miR-196b are 
highly correlated with its neighboring gene HOXA10[18]. 
A previous study showed that expression patterns of  
miR-196b were inversely correlated with the methylation 
status of  promoter CpG-rich regions in gastric cancer 
cell lines and primary gastric cancer samples[19]. Suzuki 
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Figure 5  Aberrant protein expression in gastric cancer. A: Representative 
image from the homeobox A10 (HOXA10) immunohistochemical assay (× 200) 
of gastric cancer tissue. The moderately differentiated adenocarcinoma shows 
positive for HOXA10 expression. A strong cytoplasmic immunoreaction was 
noted; B: Negative for HOXA10 expression; C: The expression pattern of 48 
proteins from Reverse-phase protein array (RPPA) was depicted using a heat 
map. The color yellow represents relatively high expression levels and blue 
reflects relatively low levels.
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et al[46] analyzed genome-wide profiling of  chromatin 
signatures combining microRNA expression and sug-
gested that DNA demethylation can alter the chromatin 
signatures of  numerous microRNAs in cancer. Elevated 
expression of  miR-196b in gastric cancer cells may result 
from the preferential unmethylated status of  CpG islands 
and from other TFs. We suggest that HOXA10 expres-
sion might also be governed by miR-196b modulation; 
however, the exact mechanism of  miR-196b promoter 
activity modulation by TFs remains to be elucidated.
In the present study, miR-196b and HOXA10 were 
co-activated in gastric cancer samples, especially in the 
poor-prognosis group. miR-196b and HOXA10 are also 
closely related to the development and progression of  
hematopoietic stem cells. This suggests that gastric can-
cer co-activated by miR-196b and HOXA10 might share 
the same pathogenesis as leukemia. Chronic inflamma-
tion caused by Helicobacter pylori (H. pylori) is associated 
with gastric carcinogenesis and there is recent evidence 
that H. pylori infection recruits bone marrow-derived cells 
(BMDCs) in the gastric epithelial mucosa that participate 
in gastric preneoplasia[47,48]. Over-expression of  miR-
196b and HOXA10 may mediate the development of  
hematopoietic progenitor cells and gastric cancer; thus, it 
is necessary to elucidate the mechanism and function of  
the co-activation of  miR-196b and HOXA10 in gastric 
cancer.
RPPA is a quantitative assay that analyzes large 
samples for known proteins and their active forms. We 
evaluated the expression of  124 proteins to understand 
the physiology and pathogenesis of  gastric cancer at the 
protein level. The limitations of  this platform, measur-
ing only small numbers of  known antibodies, were taken 
into consideration when interpreting the data. As shown 
in Figure 5B, protein expression patterns are highly het-
erogeneous, even between gastric cancers, indicating 
that a few tumor targets will apply to almost all patients 
with gastric cancer and that most markers are likely to 
only apply to selected patients. In the present study, 
COX2 and cyclin B1 were significantly elevated in the 
C1 group compared with the C2 group. In combination 
with gene expression array data, the HOXA10 promoter 
has a nuclear factor-κB (NFκB) binding site, and NFκB 
controls COX2 expression, leading to inflammation and 
carcinogenesis. The elucidation of  this relationship might 
explain the mechanism of  HOXA10 over-expression in 
gastric cancer.
In conclusion, using an integrative analysis of  tumor 
transcriptome and protein expression data by microar-
ray techniques, we have elucidated the molecular biologic 
characteristics of  a poor-prognosis gastric cancer sub-
group. We postulate that the overexpression of  miR-196b 
and HOXA10 are implicated in gastric cancer, particu-
larly in tumors with poor-prognosis features. The person-
alized cancer therapy targets aberrations that drive tumor 
growth and survival. Administering the right drug for the 
right person consequently improves clinical outcomes 
and decreases toxicity. We anticipate that this approach 
will contribute to the characterization of  cancer hetero-
geneity and the development of  personalized therapy 
through the identification of  cancer targets. 
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COMMENTS
Background
Gastric cancer is clinically heterogenous, which suggest underlying molecular 
diversity. Advances in high-throughput technologies such as microarray for gene 
or protein expression profiles have reinforced the identification of molecular bio-
logic characteristics of cancer. It is of great clinical value to perform integrative 
analysis of data from diverse high-throughput technologies simultaneously, to 
elucidate gastric cancer subtype harboring poor prognosis. 
Research frontiers
MicroRNAs play a role in the pathogenesis of various human cancers by 
regulating the expression of target gene post transcriptionally. Microarray and 
bioinformatic technologies enable the investigation of the trans-correlation of 
hundreds of microRNAs and tens of thousands of genes. 
Innovations and breakthroughs
MiR-196b was the most significantly up-regulated microRNA in gastric cancer 
and was significantly correlated with poor prognosis. The expression of miR-
196b appeared to be most positively associated with homeobox A10 (HOXA10) 
expression. The expression of miR-196b and HOXA10 seems to be regulated 
by identical biologic mechanism and characterize a poor-prognosis gastric can-
cer subtype.
Table 2  microRNAs differentially expressed in gastric cancer tissues; non-cancer tissue and C1 and C2 groups (P  < 0.05)
Name Chromosome 
location
Function Related gene Related cancer References
Expression level: C1 > C2 > non-cancer 
hsa-miR-196b 7p15.2 Tumor suppressor, 
progression
HOXA, HOXC8 T-cell ALL, MLL-rearranged leukemia, ALL, 
stomach, lung, pancreas
18,19,27,28
hsa-miR-135b 1q32.1 Tumorigenesis FOXO1, APC Leukemia, anaplastic large cell lymphoma, 
pancreas, colon, prostate, osteosarcoma
29-31
hsa-miR-93 7q22.1 Tumorigenesis, 
progression, prognosis
E2F1, ZBTB4, FUS1, TP53INP1, 
ITGB8, VEGFA, CDKN1A
Kidney, breast, colon, liver, stomach, lung, 
osteosarcoma, adult T-cell leukemia
17,32-37
Expression level: C1 < C2 < non-cancer 
hsa-miR-29c* 1q32.2 Prognosis Malignant pleural mesothelioma 38
ALL: Acute lymphoblastic leukemia; MLL: Mixed lineage leukemia gene; HOXA10: Homeobox A10.
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Applications
An integrative approach that simultaneously evaluates the expression profiles 
of mRNA, microRNA, and protein in cancer tissue will contribute to character-
izing cancer heterogeneity and developing personalized therapy through the 
identification of cancer targets.
Terminology
A microarray is a multiplex lab-on-a-chip and assays large amounts of biological 
material using high-throughput screening methods. The types of microarrays 
include DNA microarray, microRNA microarray, protein microarray, and tissue 
microarray. Bioinformatics is the analysis of biological data including gene and 
protein expression and regulation data. 
Peer review
This study generated and analyzed gene, microRNA, and protein expression 
profiles from 60 patients with gastric cancer and identified the overexpression 
of miR-196b and HOXA10 as a characteristic of a poor-prognosis gastric can-
cer subtype. Further investigation to elucidate the molecular biologic function of 
miR-196b and HOXA10 in gastric cancer is necessary.
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